Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
24
KZIA Quote, Financials, Valuation and Earnings
Last price:
$6.72
Seasonality move
:
15.2%
Day range:
$6.25 - $6.93
52-week range:
$2.86 - $17.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
311.32x
P/B ratio:
2.19x
Volume:
144.8K
Avg. volume:
1.4M
1-year change:
-22.15%
Market cap:
$11.5M
Revenue:
$27.2K
EPS (TTM):
-$6.67
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -- | -- | $19.01 |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | $12.00 |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | $9.50 |
|
IMRN
Immuron Ltd.
|
-- | -- | -- | -- | -- |
|
MESO
Mesoblast Ltd.
|
$23M | -- | -100% | -- | $35.00 |
|
PPCB
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KZIA
Kazia Therapeutics Ltd.
|
$6.89 | $19.01 | $11.5M | -- | $0.00 | 0% | 311.32x |
|
ATHE
Alterity Therapeutics Ltd.
|
$3.08 | $12.00 | $55.8M | -- | $0.00 | 0% | 3.58x |
|
IMMP
Immutep Ltd.
|
$2.86 | $9.50 | $416.3M | -- | $0.00 | 0% | -- |
|
IMRN
Immuron Ltd.
|
$0.76 | -- | $4.4M | -- | $0.00 | 0% | 0.93x |
|
MESO
Mesoblast Ltd.
|
$18.04 | $35.00 | $2.3B | -- | $0.00 | 0% | 126.61x |
|
PPCB
|
$11.98 | -- | $158.1K | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KZIA
Kazia Therapeutics Ltd.
|
-6.76% | 4.217 | 5.57% | 0.07x |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | 2.761 | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | 0.437 | -- | -- |
|
IMRN
Immuron Ltd.
|
-- | 1.243 | -- | 5.77x |
|
MESO
Mesoblast Ltd.
|
-- | 2.583 | -- | -- |
|
PPCB
|
-- | 4.794 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -784.09% | -1083.16% | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | -- | -- |
|
IMRN
Immuron Ltd.
|
-- | -- | -53.91% | -53.91% | -- | -- |
|
MESO
Mesoblast Ltd.
|
-- | -- | -- | -- | -- | -- |
|
PPCB
|
-- | -$290.8K | -- | -- | -- | -$235.5K |
Kazia Therapeutics Ltd. vs. Competitors
-
Which has Higher Returns KZIA or ATHE?
Alterity Therapeutics Ltd. has a net margin of -- compared to Kazia Therapeutics Ltd.'s net margin of --. Kazia Therapeutics Ltd.'s return on equity of -1083.16% beat Alterity Therapeutics Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KZIAKazia Therapeutics Ltd.-- -- -$6.3M ATHEAlterity Therapeutics Ltd.-- -- -- -
What do Analysts Say About KZIA or ATHE?
Kazia Therapeutics Ltd. has a consensus price target of $19.01, signalling upside risk potential of 176.4%. On the other hand Alterity Therapeutics Ltd. has an analysts' consensus of $12.00 which suggests that it could grow by 289.61%. Given that Alterity Therapeutics Ltd. has higher upside potential than Kazia Therapeutics Ltd., analysts believe Alterity Therapeutics Ltd. is more attractive than Kazia Therapeutics Ltd..
Company Buy Ratings Hold Ratings Sell Ratings KZIAKazia Therapeutics Ltd.1 0 0 ATHEAlterity Therapeutics Ltd.0 0 0 -
Is KZIA or ATHE More Risky?
Kazia Therapeutics Ltd. has a beta of 1.739, which suggesting that the stock is 73.892% more volatile than S&P 500. In comparison Alterity Therapeutics Ltd. has a beta of 0.065, suggesting its less volatile than the S&P 500 by 93.549%.
-
Which is a Better Dividend Stock KZIA or ATHE?
Kazia Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alterity Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kazia Therapeutics Ltd. pays -- of its earnings as a dividend. Alterity Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KZIA or ATHE?
Kazia Therapeutics Ltd. quarterly revenues are --, which are smaller than Alterity Therapeutics Ltd. quarterly revenues of --. Kazia Therapeutics Ltd.'s net income of -- is lower than Alterity Therapeutics Ltd.'s net income of --. Notably, Kazia Therapeutics Ltd.'s price-to-earnings ratio is -- while Alterity Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kazia Therapeutics Ltd. is 311.32x versus 3.58x for Alterity Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KZIAKazia Therapeutics Ltd.311.32x -- -- -- ATHEAlterity Therapeutics Ltd.3.58x -- -- --
-
Which has Higher Returns KZIA or IMMP?
Immutep Ltd. has a net margin of -- compared to Kazia Therapeutics Ltd.'s net margin of --. Kazia Therapeutics Ltd.'s return on equity of -1083.16% beat Immutep Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KZIAKazia Therapeutics Ltd.-- -- -$6.3M IMMPImmutep Ltd.-- -- -- -
What do Analysts Say About KZIA or IMMP?
Kazia Therapeutics Ltd. has a consensus price target of $19.01, signalling upside risk potential of 176.4%. On the other hand Immutep Ltd. has an analysts' consensus of $9.50 which suggests that it could grow by 232.17%. Given that Immutep Ltd. has higher upside potential than Kazia Therapeutics Ltd., analysts believe Immutep Ltd. is more attractive than Kazia Therapeutics Ltd..
Company Buy Ratings Hold Ratings Sell Ratings KZIAKazia Therapeutics Ltd.1 0 0 IMMPImmutep Ltd.1 0 0 -
Is KZIA or IMMP More Risky?
Kazia Therapeutics Ltd. has a beta of 1.739, which suggesting that the stock is 73.892% more volatile than S&P 500. In comparison Immutep Ltd. has a beta of 1.758, suggesting its more volatile than the S&P 500 by 75.781%.
-
Which is a Better Dividend Stock KZIA or IMMP?
Kazia Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immutep Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kazia Therapeutics Ltd. pays -- of its earnings as a dividend. Immutep Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KZIA or IMMP?
Kazia Therapeutics Ltd. quarterly revenues are --, which are smaller than Immutep Ltd. quarterly revenues of --. Kazia Therapeutics Ltd.'s net income of -- is lower than Immutep Ltd.'s net income of --. Notably, Kazia Therapeutics Ltd.'s price-to-earnings ratio is -- while Immutep Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kazia Therapeutics Ltd. is 311.32x versus -- for Immutep Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KZIAKazia Therapeutics Ltd.311.32x -- -- -- IMMPImmutep Ltd.-- -- -- --
-
Which has Higher Returns KZIA or IMRN?
Immuron Ltd. has a net margin of -- compared to Kazia Therapeutics Ltd.'s net margin of --. Kazia Therapeutics Ltd.'s return on equity of -1083.16% beat Immuron Ltd.'s return on equity of -53.91%.
Company Gross Margin Earnings Per Share Invested Capital KZIAKazia Therapeutics Ltd.-- -- -$6.3M IMRNImmuron Ltd.-- -- $6.4M -
What do Analysts Say About KZIA or IMRN?
Kazia Therapeutics Ltd. has a consensus price target of $19.01, signalling upside risk potential of 176.4%. On the other hand Immuron Ltd. has an analysts' consensus of -- which suggests that it could grow by 425.01%. Given that Immuron Ltd. has higher upside potential than Kazia Therapeutics Ltd., analysts believe Immuron Ltd. is more attractive than Kazia Therapeutics Ltd..
Company Buy Ratings Hold Ratings Sell Ratings KZIAKazia Therapeutics Ltd.1 0 0 IMRNImmuron Ltd.0 0 0 -
Is KZIA or IMRN More Risky?
Kazia Therapeutics Ltd. has a beta of 1.739, which suggesting that the stock is 73.892% more volatile than S&P 500. In comparison Immuron Ltd. has a beta of 0.794, suggesting its less volatile than the S&P 500 by 20.554%.
-
Which is a Better Dividend Stock KZIA or IMRN?
Kazia Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immuron Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kazia Therapeutics Ltd. pays -- of its earnings as a dividend. Immuron Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KZIA or IMRN?
Kazia Therapeutics Ltd. quarterly revenues are --, which are smaller than Immuron Ltd. quarterly revenues of --. Kazia Therapeutics Ltd.'s net income of -- is lower than Immuron Ltd.'s net income of --. Notably, Kazia Therapeutics Ltd.'s price-to-earnings ratio is -- while Immuron Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kazia Therapeutics Ltd. is 311.32x versus 0.93x for Immuron Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KZIAKazia Therapeutics Ltd.311.32x -- -- -- IMRNImmuron Ltd.0.93x -- -- --
-
Which has Higher Returns KZIA or MESO?
Mesoblast Ltd. has a net margin of -- compared to Kazia Therapeutics Ltd.'s net margin of --. Kazia Therapeutics Ltd.'s return on equity of -1083.16% beat Mesoblast Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KZIAKazia Therapeutics Ltd.-- -- -$6.3M MESOMesoblast Ltd.-- -- -- -
What do Analysts Say About KZIA or MESO?
Kazia Therapeutics Ltd. has a consensus price target of $19.01, signalling upside risk potential of 176.4%. On the other hand Mesoblast Ltd. has an analysts' consensus of $35.00 which suggests that it could grow by 94.01%. Given that Kazia Therapeutics Ltd. has higher upside potential than Mesoblast Ltd., analysts believe Kazia Therapeutics Ltd. is more attractive than Mesoblast Ltd..
Company Buy Ratings Hold Ratings Sell Ratings KZIAKazia Therapeutics Ltd.1 0 0 MESOMesoblast Ltd.1 0 0 -
Is KZIA or MESO More Risky?
Kazia Therapeutics Ltd. has a beta of 1.739, which suggesting that the stock is 73.892% more volatile than S&P 500. In comparison Mesoblast Ltd. has a beta of 2.140, suggesting its more volatile than the S&P 500 by 113.996%.
-
Which is a Better Dividend Stock KZIA or MESO?
Kazia Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mesoblast Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kazia Therapeutics Ltd. pays -- of its earnings as a dividend. Mesoblast Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KZIA or MESO?
Kazia Therapeutics Ltd. quarterly revenues are --, which are smaller than Mesoblast Ltd. quarterly revenues of --. Kazia Therapeutics Ltd.'s net income of -- is lower than Mesoblast Ltd.'s net income of --. Notably, Kazia Therapeutics Ltd.'s price-to-earnings ratio is -- while Mesoblast Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kazia Therapeutics Ltd. is 311.32x versus 126.61x for Mesoblast Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KZIAKazia Therapeutics Ltd.311.32x -- -- -- MESOMesoblast Ltd.126.61x -- -- --
-
Which has Higher Returns KZIA or PPCB?
has a net margin of -- compared to Kazia Therapeutics Ltd.'s net margin of --. Kazia Therapeutics Ltd.'s return on equity of -1083.16% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KZIAKazia Therapeutics Ltd.-- -- -$6.3M PPCB-- -$0.00 -- -
What do Analysts Say About KZIA or PPCB?
Kazia Therapeutics Ltd. has a consensus price target of $19.01, signalling upside risk potential of 176.4%. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Kazia Therapeutics Ltd. has higher upside potential than , analysts believe Kazia Therapeutics Ltd. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings KZIAKazia Therapeutics Ltd.1 0 0 PPCB0 0 0 -
Is KZIA or PPCB More Risky?
Kazia Therapeutics Ltd. has a beta of 1.739, which suggesting that the stock is 73.892% more volatile than S&P 500. In comparison has a beta of 1.881, suggesting its more volatile than the S&P 500 by 88.104%.
-
Which is a Better Dividend Stock KZIA or PPCB?
Kazia Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kazia Therapeutics Ltd. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KZIA or PPCB?
Kazia Therapeutics Ltd. quarterly revenues are --, which are smaller than quarterly revenues of --. Kazia Therapeutics Ltd.'s net income of -- is lower than 's net income of -$354.3K. Notably, Kazia Therapeutics Ltd.'s price-to-earnings ratio is -- while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kazia Therapeutics Ltd. is 311.32x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KZIAKazia Therapeutics Ltd.311.32x -- -- -- PPCB-- -- -- -$354.3K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Buy
81
ZIJMY alert for Jan 1
Zijin Mining Group Co., Ltd. [ZIJMY] is up 1.86% over the past day.
